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a b s t r a c t
Having a history of infection with one pathogen may sometimes provide a level of T cell-dependent
protective heterologous immunity to another pathogen. This immunity was initially thought due to
cross-reactive T cell epitopes, but recent work has suggested that such protective immunity can be
initiated nonspeciﬁcally by the action of cytokines on memory T cells. We retested this concept using
two small and well-deﬁned arenaviruses, lymphocytic choriomeningitis virus (LCMV) and Pichinde virus
(PV), and found that heterologous immunity in these systems was indeed linked to T cell epitopes and
the major histocompatibility complex.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The term heterologous immunity refers to the phenomenon
whereby a previous exposure of an immune system to one
pathogen will alter the host response to a second heterologous
pathogen (Welsh et al., 2010). The mechanisms of heterologous
immunity can be varied and involve both innate and adaptive
components of the immune system. T cell-dependent heterolo-
gous immunity refers to the ability of memory T cells to provide
beneﬁcial or detrimental immunity to another pathogen. T cell
cross-reactivity against epitopes expressed by heterologous patho-
gens is quite common, and initial studies on T cell-dependent
heterologous immunity implicated such cross-reactive T cells in
this process (Welsh and Selin, 2002). However, there have been
a series of reports indicating that a number of cytokines, such
as IL-12 and IL-18, may be able to “non-speciﬁcally” activate
memory T cells, thereby enabling them to provide resistance to
certain pathogens by the generation of interferon (IFN)γ
(Gilbertson et al., 2004; Raue et al., 2004; Berg et al., 2002).
Recent reports have suggested that these T cells may also express
the receptor NKG2D and be able to recognize stress-related
ligands expressed on pathogen-infected cells (Chu et al., 2013;
Hamerman et al., 2004).
Proving that T cell cross-reactivity is not occurring in these
types of studies is challenging, given that cross-reactivity becomes
increasingly more difﬁcult to disprove as the functional avidity
between putative cross-reactive epitopes declines. A recent study,
using a green ﬂuorescent protein (GFP)-nur77 transgenic mouse,
whose T cells up-regulate GFP expression if their TCR is stimulated,
showed some greening of the memory T cells putatively nonspe-
ciﬁcally stimulated by pathogen-induced cytokines (Hamerman et
al., 2004). Cytokines like type 1 IFN can up-regulate MHC and co-
stimulatory antigens and cause a partial activation of naïve T cells
in the form of expression of the effector cell transcription factor
eomesodermin (Marshall et al., 2010). This effect is seen only with
transgenic T cells that have enough reactivity with self-antigens to
undergo homeostatic proliferation and is inhibited by cyclospor-
ine, a potent inhibitor of TCR signaling. Hence, one mechanism of a
putative “non-speciﬁc” activation of memory cells could be by
elevating the effector function of cells already being signaled by
self-antigen.
We have found that vaccinia virus (VACV), a strong inducer of
IL-12 and a pathogen highly sensitive to IFNγ, replicates more
poorly in mice immune to LCMV, PV, inﬂuenza A virus, or bacillus
Calmette–Guerin (BCG) than in naïve mice (Selin et al., 1998; Chen
et al., 2001; Mathurin et al., 2009). One might initially conclude
that this had to be explained by a non-speciﬁc or self-antigen-
stimulated phenomenon, but the patterns of IFNγ production
in vivo during the ﬁrst three days of VACV infection differed with
the immunizing pathogen. After VACV infection of BCG-immune
mice memory CD4 T cells made much more IFNγ than did memory
CD8 T cells, but memory CD8 T cells in LCMV-immune mice made
much more IFNγ than did memory CD4 T cells. Statistically, there
are many possibilities for cross-reactive T cell epitopes between
these very large pathogens, and, in fact, protective cross-reactive
CD8 T cell epitopes have been deﬁned between VACV and LCMV
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(Kim et al., 2005; Cornberg et al., 2007). However, just because
T cell cross-reactivity can be shown does not mean that it is the
predominant mechanism of protective heterologous immunity.
To address the mechanism of pathogen-cross-reactive T cells in
protective heterologous immunity we focused on much less
antigenically diverse pathogens, LCMV and PV. LCMV and PV are
arenaviruses that each encode only four proteins, making studies
on cross-reactive T cell epitopes much more manageable (Peters et
al., 1996). In C57BL/6 (B6) mice, LCMV and PV encode cross-
reactive MHC Kb-restricted epitopes that have 6 of 8 amino acids
in common: LCMV-NP205-212 (YTVKYPNL) and PV-NP205-212
(YTVKFPNM) (Brehm et al., 2002). T cell responses to these
epitopes are normally weak, but in mice immune to one virus
and challenged by the other, they become immunodominant, and
protective T cell-dependent heterologous immunity is seen. Stu-
dies with naturally selected or genetically engineered LCMV
mutants in this epitope showed that the protective heterologous
immunity between LCMV and PV was mostly lost (Chen et al.,
2012). This was evidence that true T cell cross-reactivity was
responsible for heterologous immunity in this system. However,
given the new ﬁndings on “non-speciﬁc” heterologous immunity,
we thought it important to address this in more detail and used
these viruses to address the MHC basis of heterologous immunity.
To examine this process we ﬁrst employed commonly used
laboratory strains of mice (B6, BALB/c, CBA) harboring differing
MHC complexes. Then to determine whether any differences seen
in pathogenesis were related to the MHC, we employed MHC-
diverse congenic mice on the same C57BL/10 (B10) genetic
background.
Results and discussion
Initially we examined the ability of a history of an LCMV
infection to provide protective heterologous immunity to acute
PV infection. Table 1, experiment 1, lists a representative
experiment done at the time of these studies showing that PV
replicates to over 10-fold higher titers in naïve mice than in LCMV-
immune B6 (H2b) mice. This heterologous immunity in B6 mice
has been documented extensively in previous studies (Brehm et
al., 2002; Cornberg et al., 2006; Chen et al., 2012). It is associated
with a change in CD8 T cell immunodominance such that the
normally subdominant cross-reactive NP205 epitope becomes
immunodominant. Further, LCMV variants mutant in the NP205
epitope fail to provide heterologous immunity against PV. This
heterologous immunity is reciprocal, though LCMV-immune mice
protect better against PV than do PV-immune mice against LCMV,
probably because more NP205-speciﬁc T cells are in the LCMV-
induced memory pool.
Experiments 2 and 3 show two similar experiments with B10
mice. These mice are closely related to B6, and they exhibited the
same pattern of heterologous immunity, where a history of an
LCMV infection strongly protected against PV. Of note is that in
experiments 1–3 the variation in PV titers was higher in the
LCMV-immune mice than in the non-immunized mice. This is a
commonly observed phenomenon in heterologous immunity stu-
dies and is a consequence of variations in the memory pools
caused by the private speciﬁcities of the immune repertoires in the
immune mice (Cornberg et al., 2006; Kim et al., 2005). We have
shown that, depending on the individual immune B6 mouse, the
magnitude of the cross-reactive response may vary from 5% to 30%
(Cornberg et al., 2006), making the assessment of mean titers not
always the best way to measure the protective capacity. However,
since T cell cross-reactivity and protective heterologous immunity
are so strong between these arenaviruses in mice with an MHC
haplotype of b, such protection can easily be demonstrated.
Experiments 4–8 examine heterologous immunity in two
strains of mice expressing an MHC of k: CBA and B10.BR. The
B10.BR mice are congenic with B10 mice, except for the MHC
region, which contains immune system genes with k alleles rather
than b alleles. None of the ﬁve experiments showed any statistical
differences in the mean viral titers between PV-challenged naïve
mice and LCMV-immune groups. In three of the experiments titers
were slightly higher in the naïve group, and in two of the
experiments titers were slightly higher in the immune group,
but none of the differences approached signiﬁcance. Given that the
B10.BR mice differ from the B10 mice only in the MHC, this
experiment would argue that protective heterologous immunity
between these two viruses was linked to the H2b vs. H2k MHC
differences of these strains of mice.
Studies done with BALB/c and B10.D2 mice, which have an
MHC haplotype of d, were a bit more complex and revealed a
phenotype that suggested heterologous immunity but at a weaker
level than that seen with the H2b mice. In each of the 5 experi-
ments (#9–13) the means of the PV titers in LCMV-immune mice
were lower than those in the naïve mice, averaging to about a
0.7 log (5-fold) difference in titer. The individual experiments
differed in their levels of signiﬁcance. Two (experiments 10 and
13) were highly signiﬁcant, one (experiment 9) was borderline,
and two (experiments 11 and 12) registered as non-signiﬁcant.
However the two non-signiﬁcant experiments had very high
standard deviations in the LCMV-immune group, an event com-
monly seen with heterologous immunity due to the private
speciﬁcities of the immune repertoires, as mentioned above. Given
this suggestion of heterologous immunity between LCMV and PV
in H2d mice, we tested its reciprocal nature by challenging PV-
immune H2d mice with LCMV. Experiments 14 and 15 in Table 1
show that a history of PV infection did provide heterologous
immunity to LCMV in these H2d-expressing mice, supporting the
idea that heterologous immunity between these two viruses does
occur in the context of MHC of d, but perhaps not as strongly as in
the context of MHC of b. In contrast, one experiment (16) showed
Table 1
Replication of virus in the spleen of naïve or immune mice.
Experiment Mouse (MHC) Naïve/PV LCMV-imm/PV P
1. C57BL/6 (b) 2.970.2 (5) 1.470.7 (4) 0.002
2. B10 (b) 3.370.5 (5 ) 1.570.7 (5) 0.002
3. B10 (b) 3.870.3 (2) 1.970.7 (4) 0.025
4. CBA (k) 5.470.04 (5) 5.570.2 (5) 0.30 (NS)
5. CBA (k) 5.870.5 (5) 5.270.8 (5) 0.60 (NS)
6. B10.BR (k) 3.770.6 (4) 3.270.5 (4) 0.25 (NS)
7. B10.BR (k) 3.570.6 (2) 3.770.5 (4) 0.68 (NS)
8. B10.BR (k) 3.870.5 (5) 3.770.4 (5) 0.35 (NS)
9. BALB/c (d) 5.670.4 (4) 5.170.2 (4) 0.067
10. BALB/c (d) 5.670.2 (4) 5.370.1 (4) 0.036
11. B10.D2 (d) 3.370.6 (5) 2.971.1 (5) 0.49 (NS)
12. B10.D2 (d) 4.570.5 (2) 3.471.3 (4) 0.33 (NS)
13. B10.D2 (d) 4.270.5 (5) 3.170.3 (4) 0.04
Naïve/LCMVPV-imm/LCMV Naïve/LCMV PV-imm/LCMV
14. BALB/c (d) 4.570.63 (4) 3.870.3 (4) 0.08
15. BALB/c (d) 5.170.02 (4) 4.070.7 (4) 0.02
16. CBA (k) 4.670.05 (5) 4.470.05 (5) 0.0002
Age-matched male mice 5–10 weeks of age were immunized i.p. with 100 ml of
either 5104 PFU of LCMV diluted 70-fold from stock virus into serum-free Hank's
Balanced Salt Solution (HBSS), 107 PFU of PV puriﬁed in sucrose gradients and
diluted in HBSS, or HBSS only (Naïve control). A higher dose of PV was used because
this stock of PV does not replicate as well in mice as LCMV. After at least 6 weeks
the mice were given heterologous challenges with similar doses of LCMV or PV.
Four days after challenge spleens were harvested, and spleen suspensions were
analyzed for PFU. Data presented are the mean7standard deviation, with the
number of mice per group in parentheses. Experiments were designed with n¼4–5
per group. In three experiments (#3, 7, and 12) there was unexpected death of
some mice prior to challenge. In this table we decided to present all the data we
had rather than to delete those experiments.
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very little protective heterologous immunity in this PVþLCMV
virus sequence in CBA (H2k) mice, much like the lack of differences
seen in the LCMVþPV sequence in other H2k mice. While the
degree of protection in H2d mice was variable and modest
compared to what was observed in the H2b haplotype, it is
important to note that no protection was ever observed in H2k
mice, indicating that heterologous immunity between these
viruses is an MHC-dependent phenomenon that indeed exists in
the H2d haplotype although not as robustly as in the H2b
haplotype.
Based on the results shown in Table 1 indicating modest MHC-
linked heterologous immunity in H2d mice, we hypothesized that
there may be H2d-restricted T cell epitopes cross-reactive between
LCMV and PV. LCMV-speciﬁc CD8 T cell epitopes have been
identiﬁed on an H2d background, but no H2d-epitopes for PV
had previously been identiﬁed. Initial screens done with BALB/c
mice used Elispots and intracellular cytokine assays for detecting
IFNγ after exposure of splenocytes or PEC to overlapping peptides
of the LCMV and PV GP and NP proteins. These initially yielded a
number of positive results and potential cross reactive candidates,
but subsequent examination of these peptides resulted in only an
individual CD8 peptide from both viruses that scored consistently
over the no peptide background. The positive epitope was con-
tained within the LCMV peptide NP309–326 and the PV peptide
NP311–330. The nucleoprotein (NP) is the most highly expressed
protein for each of these viruses. Using predicted binding motifs
for class 1 MHC epitopes we deﬁned two possible epitopes located
within the LCMV and PV peptides. These consisted of the puta-
tively Ld-restricted epitopes LCMV NP313–322 (WPYIACRTSI) and
PV NP313–322 (WPYIGSRSQV) as well as putative Kd-restricted
epitopes LCMV NP314–322 (PYIACRTSI) and PV NP314
(PYIGSRSQV), with the underlined being anchoring amino acids.
Previous work with LCMV had identiﬁed the subdominant epitope
NP313 through the use of DNA minigene protection assays
(Rodriguez et al., 2001). However, the LCMV peptide beginning
at NP314 was not considered a true epitope (van der Most et al.,
1996). We synthesized all four peptides and were able to conﬁrm
the previously published ﬁndings for these epitopes during an
acute LCMV infection (Fig. 1A and B).
Fig. 1 shows the LCMV- and PV-induced CD8 T cell responses to
the four epitopes in the spleen (A) and PEC (B) of BALB/c mice
infected for 8 days with either LCMV or PV. In general stronger
results were seen within the PEC, reﬂecting the inoculation route
of the virus. The LCMV and PV NP313 epitopes were both
recognized by LCMV- or PV-induced T cell populations, though
the PV-induced populations only weakly recognized the LCMV
NP313, while more strongly recognizing the PV313. The PV-induced
populations also recognized PV-encoded NP314, and it is unclear
Fig. 1. Cross-reactive epitopes in BALB/c (H2d) mice. (A,B) After preliminary screening efforts to detect cross-reactive epitopes, BALB/c mice were inoculated with LCMV or
PV as described in Table 1. At day 8 post-infection splenocytes (A) or peritoneal exudate cells (PEC) (B) were exposed to the four putative cross-reactive epitopes encoded by
LCMV and by PV and deﬁned in the text. These were tested in intracellular cytokine assays after stimulation with 1 mM peptide and gated on CD8 T cells. Solid horizontal lines
mark the means of the plotted samples showing reactivity. Horizontal dashed lines show the levels of background staining without peptide. C and D show enhanced
reactivity to the NP313 epitopes in mice immune to one virus and then challenged with the other at 8 days post-infection. For clarity of the ﬁgure, data for unchallenged
immune controls are not plotted. However, in unchallenged LCMV-immune or PV-immune BALB/c mice, less than 0.5% of the spleen CD8 cells reacted with any of the
peptides. Less than 2.5% of CD8 T cells in the PEC reacted with any of the peptides, and the number of CD8 T cells in the PEC expanded greater than 10-fold by day 8.
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whether some of the PV-encoded NP313 was cleaved into the NP314
form. Recognition of NP314 by LCMV-induced populations was, as
previously reported (van der Most et al., 1996), negligible.
Fig. 1C and D displays the day 8 T cell response to these four
peptides in mice immune to one virus and challenged with
another. Again the PEC T cell responses were much stronger than
those in the spleen. LCMV-immune mice challenged with PV
developed a strong dominant T cell response to each of the
NP313 epitopes, ranging in the 4–5% range. This was not as strong
as that seen against the NP205 epitope in H2b mice, perhaps
consistent with the heterologous immunity in these H2d mice
being not as profound. The CD8 T cell response was also greater in
LCMV-immune mice challenged with PV compared to PV-immune
mice challenged with LCMV (Fig. 1C and D), perhaps reﬂecting the
fact that the frequency of spleen LCMV NP313-speciﬁc T cells was
higher in LCMV-immune (0.26%) mice than in PV-immune mice
(o0.1%). The response against the PV-encoded NP313 was much
stronger than that against the PV-encoded NP314, arguing that it
was probably truly against the intact Ld-restricted NP313 and not a
NP314 breakdown product presented by Kd. The heterologous
immune response in PV-immune mice challenged with LCMV
was not as strong (Fig. 2) and was not much different at this day
8 time point from non-immune mice acutely infected with LCMV
(Fig. 1).
The design of our experiments in Table 1 to measure hetero-
logous immunity was to titrate virus at day 4, which we also found
was a good time point to examine the development of the early
heterologous CD8 T cell responses from the PEC, which had
migrated into the site of initial viral inoculation. To conﬁrm the
MHC-restricted nature of the heterologous immune response to
the deﬁned peptide epitopes, we show in Fig. 2 the PEC T cell
response to the cross-reactive NP313 epitopes encoded by LCMV
and PV in MHC congenic mice immune to LCMV and challenged
with PV. Readily detectable responses were made against both
epitopes in the immune B10.D2 mice, whereas the responses in
the B10 and B10.BR mice were negligible and at background levels.
This use of the congenic B10-series mice further demonstrates the
MHC-restriction of the cross-reactive epitope.
The results of this study support the argument that protective
heterologous immunity between distantly related agents can be
mediated rather selectively, be dependent on the MHC of the host,
and be correlated with the presence of cross-reactive epitopes.
Further analysis in this system with mutants in the cross-reactive
H2d epitopes, as we have done previously with the H2b haplotype
(Chen et al., 2012), will be needed to provide the deﬁnitive link
between cross-reactive CD8 T cell populations and heterologous
immunity between LCMV and PV in H2d mice. These results are
inconsistent with the frequently promoted idea that memory cells
get non-speciﬁcally stimulated and provide non-speciﬁc protec-
tion against infection through the release of cytokines like IFNγ or
through non-speciﬁc attack on stressed target cells mediated
through innate sensors (Gilbertson et al., 2004; Raue et al.,
2004; Berg et al., 2002; Chu et al., 2013; Hamerman et al., 2004).
However, our study does not mean that those situations do not
occur. Rather, it means that they do not have to occur for the
protective capacities of heterologous immunity to be manifested.
LCMV and PV may not induce enough of the appropriate cytokines,
such as IL-12, to non-speciﬁcally activate memory cells. Further,
these viruses may not be sensitive enough to IFNγ to be affected by
that mechanism, and, being relatively non-cytopathic, they may
not stress infected cells sufﬁciently to induce ligands for stress-
detecting receptors. These viruses do, however, provide a simple
system to more clearly deﬁne the mechanisms of heterologous
immunity. In B6 mice the speciﬁc role of CD4 and CD8 T cells in
mediating heterologous immunity between these pathogens is
well established and helped by the fact that each virus encodes
only four proteins (Brehm et al., 2002; Cornberg et al., 2006; Chen
et al., 2012; Selin et al., 1998). With larger and more complicated
Fig. 2. MHC restriction of the cross-reactive epitopes. This ﬁgure plots the CD8 T cell responses to the deﬁned cross-reactive LCMV and PV NP313 epitopes under conditions
of LCMVþPV heterologous immunity, as described in Table 1. This plots the activity in PEC CD8 T cells at day 4 post-infection. Here, the B10 series of mice is examined, and
only those expressing H2d (B10.D2, like the H2d-expressing BALB/c mice (Fig. 1)), show positive reactivity to the two peptides, thereby demonstrating MHC-restriction.
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viral or bacterial pathogens, it may be tempting to conclude that
the heterologous immunity is a non-speciﬁc function because it is
so difﬁcult to deﬁne the cross-reactive elements between the
pathogens.
We believe that the more one looks for T cell cross-reactivity,
the more one ﬁnds it, but the evidence for non-speciﬁc factors
regulating heterologous immunity must be considered and appre-
ciated. We predict that the mechanisms of heterologous immunity
will be diverse and depend greatly with the pathogens being
examined.
Acknowledgments
These studies were supported by U.S. P.H.S. National Institutes
of Health Grants AI 081675 and AI 046629. The opinions expressed
are those of the authors and not necessarily those of the National
Institutes of Health.
References
Berg, R.E., Cordes, C.J., Forman, J., 2002. Contribution of CD8þ T cells to innate
immunity: IFN-gamma secretion induced by IL-12 and IL-18. Eur. J. Immunol. 32,
2807–2816.
Brehm, M.A., Pinto, A.K., Daniels, K.A., Schneck, J.P., Welsh, R.M., Selin, L.K., 2002. T
cell immunodominance and maintenance of memory regulated by unexpect-
edly cross-reactive pathogens. Nat. Immunol. 3, 627–634.
Chen, A.T., Cornberg, M., Gras, S., Guillonneau, C., Rossjohn, J., Trees, A., Emonet, S.,
de la Torre, J.C., Welsh, R.M., Selin, L.K., 2012. Loss of anti-viral immunity by
infection with a virus encoding a cross-reactive pathogenic epitope. PLoS
Pathog. 8, e1002633.
Chen, H.D., Fraire, A.E., Joris, I., Brehm, M.A., Welsh, R.M., Selin, L.K., 2001. Memory
CD8þ T cells in heterologous antiviral immunity and immunopathology in the
lung. Nat. Immunol. 2, 1067–1076.
Chu, T., Tyznik, A.J., Roepke, S., Berkley, A.M., Woodward-Davis, A., Pattacini, L.,
Bevan, M.J., Zehn, D., Prlic, M., 2013. Bystander-activated memory CD8 T cells
control early pathogen load in an innate-like, NKG2D-dependent manner. Cell
Rep. 3, 701–708.
Cornberg, M., Chen, A.T., Wilkinson, L.A., Brehm, M.A., Kim, S.K., Calcagno, C.,
Ghersi, D., Puzone, R., Celada, F., Welsh, R.M., Selin, L.K., 2006. Narrowed TCR
repertoire and viral escape as a consequence of heterologous immunity. J. Clin.
Investig. 116, 1443–1456.
Cornberg, M., Sheridan, B.S., Saccoccio, F.M., Brehm, M.A., Selin, L.K., 2007.
Protection against vaccinia virus challenge by CD8 memory T cells resolved
by molecular mimicry. J. Virol. 81, 934–944.
Gilbertson, B., Germano, S., Steele, P., Turner, S., Fazekas de St, G.B., Cheers, C., 2004.
Bystander activation of CD8þ T lymphocytes during experimental mycobacter-
ial infection. Infect. Immun. 72, 6884–6891.
Hamerman, J.A., Ogasawara, K., Lanier, L.L., 2004. Cutting edge: toll-like receptor
signaling in macrophages induces ligands for the NKG2D receptor. J. Immunol.
172, 2001–2005.
Kim, S.K., Cornberg, M., Wang, X.Z., Chen, H.D., Selin, L.K., Welsh, R.M., 2005. Private
speciﬁcities of CD8 T cell responses control patterns of heterologous immunity.
J. Exp. Med. 201, 523–533.
Marshall, H.D., Prince, A.L., Berg, L.J., Welsh, R.M., 2010. IFN-alpha beta and self-
MHC divert CD8 T cells into a distinct differentiation pathway characterized by
rapid acquisition of effector functions. J. Immunol. 185, 1419–1428.
Mathurin, K.S., Martens, G.W., Kornfeld, H., Welsh, R.M., 2009. CD4 T-cell-mediated
heterologous immunity between mycobacteria and poxviruses. J. Virol. 83,
3528–3539.
Peters, C.J., Buchmeier, M., Rollin, P.E., Ksiazek, T.G., 1996. Arenaviruses. In: Fields, B.N.,
Knipe, P.M., Howley, P.M. (Eds.), Fields Virology. Lippincott-Raven, Philadelphia,
pp. 1521–1551.
Raue, H.P., Brien, J.D., Hammarlund, E., Slifka, M.K., 2004. Activation of virus-speciﬁc
CD8þ T cells by lipopolysaccharide-induced IL-12 and IL-18. J. Immunol. 173,
6873–6881.
Rodriguez, F., Slifka, M.K., Harkins, S., Whitton, J.L., 2001. Two overlapping
subdominant epitopes identiﬁed by DNA immunization induce protective
CD8(þ) T-cell populations with differing cytolytic activities. J. Virol. 75,
7399–7409.
Selin, L.K., Varga, S.M., Wong, I.C., Welsh, R.M., 1998. Protective heterologous
antiviral immunity and enhanced immunopathogenesis mediated by memory
T cell populations. J. Exp. Med. 188, 1705–1715.
van der Most, R.G., Sette, A., Oseroff, C., Alexander, J., Murali-Krishna, K., Lau, L.L.,
Southwood, S., Sidney, J., Chesnut, R.W., Matloubian, M., Ahmed, R., 1996.
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes
during acute and chronic lymphocytic choriomeningitis virus infection. J.
Immunol. 157, 5543–5554.
Welsh, R.M., Che, J.W., Brehm, M.A., Selin, L.K., 2010. Heterologous immunity
between viruses. Immunol. Rev. 235, 244–266.
Welsh, R.M., Selin, L.K., 2002. No one is naive: the signiﬁcance of heterologous T-
cell immunity. (JID - 101124169). Nat. Rev. Immunol. 2, 417–426.
K.A. Daniels et al. / Virology 464-465 (2014) 213–217 217
